Insider · CIK 0001589725

Thackray Helen M.

Reports to the SEC for 3 companies · GAITHERSBURG, MD

sec.gov

Transactions

Companies

Filings

CIK

0001589725

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-03-31	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−7,525 sh	$7.50	−$56.4K	377,318
2024-12-19	BCRXBIOCRYST PHARMACEUTICALS INCA Award	Chief R&D Officer	AAward	+126K sh	—	—	390,939
2024-12-19	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−6,096 sh	$7.39	−$45K	384,843
2024-12-19	BCRXBIOCRYST PHARMACEUTICALS INC · Emp. Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+261K sh	—	—	260,950
2024-12-14	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−7,150 sh	$7.53	−$53.8K	264,989
2024-05-14	BCRXBIOCRYST PHARMACEUTICALS INCP Purchase	Chief R&D Officer	PPurchase	+30K sh	$5.86	+$176K	272,139
2024-03-31	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−7,525 sh	$5.08	−$38.2K	242,139
2024-02-12	ImmunoGen, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,074 sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	Director	DDisposition to Issuer	−13.1K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Deferred Share UnitD Disposition to Issuer	Director	DDisposition to Issuer	−40.9K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−44K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−32.1K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.6K sh	—	—	0
2023-12-29	ImmunoGen, Inc.A Award	Director	AAward	+252 sh	$29.65	+$7,471.8	3,074
2023-12-19	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−5,580 sh	$6.05	−$33.8K	249,664
2023-12-14	BCRXBIOCRYST PHARMACEUTICALS INCA Award	Chief R&D Officer	AAward	+51K sh	—	—	258,275
2023-12-14	BCRXBIOCRYST PHARMACEUTICALS INCF Tax Payment	Chief R&D Officer	FTax Payment	−3,031 sh	$6.43	−$19.5K	255,244
2023-12-14	BCRXBIOCRYST PHARMACEUTICALS INC · Emp. Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+238K sh	—	—	238,000
2023-09-29	ImmunoGen, Inc.A Award	Director	AAward	+472 sh	$15.87	+$7,490.64	2,822
2023-06-30	ImmunoGen, Inc.A Award	Director	AAward	+397 sh	$18.87	+$7,491.39	2,350
2023-06-14	ImmunoGen, Inc.Restricted Stock UnitA Award	Director	AAward	+13.1K sh	—	—	13,090
2023-06-14	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director	AAward	+19.6K sh	—	—	19,597
2023-04-03	BCRXBIOCRYST PHARMACEUTICALS INCS Sale	Chief R&D Officer	SSale	−7,000 sh	$8.29	−$58K	207,275
2023-03-31	ImmunoGen, Inc.A Award	Director	AAward	+1,953 sh	$3.84	+$7,499.52	1,953
2022-12-19	BCRXBIOCRYST PHARMACEUTICALS INCA Award	Chief R&D Officer	AAward	+81K sh	—	—	214,275
2022-12-19	BCRXBIOCRYST PHARMACEUTICALS INC · Emp. Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+238K sh	—	—	238,000
2022-12-15	BCRXBIOCRYST PHARMACEUTICALS INCS Sale	Chief R&D Officer	SSale	−3,125 sh	$10.89	−$34K	133,275
2022-06-15	ImmunoGen, Inc.Deferred Share UnitA Award	Director	AAward	+10.9K sh	—	—	40,932
2022-06-15	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director	AAward	+32.1K sh	$3.37	+$108K	32,066
2022-04-01	BCRXBIOCRYST PHARMACEUTICALS INCS Sale	Chief R&D Officer	SSale	−7,600 sh	$16.20	−$123K	136,400
2021-12-14	BCRXBIOCRYST PHARMACEUTICALS INCA Award	Chief R&D Officer	AAward	+44K sh	—	—	144,000
2021-12-14	BCRXBIOCRYST PHARMACEUTICALS INC · Emp. Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+205K sh	—	—	205,000
2021-09-22	ImmunoGen, Inc.Deferred Share UnitA Award	Director	AAward	+30K sh	—	—	30,000
2021-09-22	ImmunoGen, Inc.Stock Option (right to buy)A Award	Director	AAward	+44K sh	$5.97	+$263K	44,000
2021-03-31	BCRXBIOCRYST PHARMACEUTICALS INCA Award	Chief R&D Officer	AAward	+100K sh	—	—	100,000
2021-03-31	BCRXBIOCRYST PHARMACEUTICALS INC · Emp. Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+400K sh	—	—	400,000
2021-01-20	CBIOCRESCENT BIOPHARMA, INC.A Award	SVP Clinical Development, CMO	AAward	+34.5K sh	—	—	183,115
2021-01-20	CBIOCRESCENT BIOPHARMA, INC. · Employee Stock Option (right to buy)A Award	SVP Clinical Development, CMO	AAward	+69K sh	—	—	69,000
2020-05-12	BCRXBIOCRYST PHARMACEUTICALS INC · Automatic Stock Option GrantA Award	Chief R&D Officer	AAward	+40K sh	—	—	40,000
2020-01-22	CBIOCRESCENT BIOPHARMA, INC. · Employee Stock Option (right to buy)A Award	SVP Clinical Development, CMO	AAward	+120K sh	—	—	120,000
2019-09-20	BCRXBIOCRYST PHARMACEUTICALS INC · Non-Qualified Stock OptionA Award	Chief R&D Officer	AAward	+40K sh	—	—	40,000
2019-01-17	CBIOCRESCENT BIOPHARMA, INC. · Employee Stock Option (right to buy)A Award	SVP Clinical Development, CMO	AAward	+100K sh	—	—	100,000
2017-12-08	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−2,000 sh	$15.01	−$30K	148,615
2017-09-18	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−2,000 sh	$13.00	−$26K	150,615
2017-05-25	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−2,000 sh	$15.57	−$31.1K	152,615
2017-05-19	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−2,000 sh	$12.14	−$24.3K	154,615
2017-01-04	CBIOCRESCENT BIOPHARMA, INC. · Employee Stock Option (right to buy)A Award	SVP Clinical Development, CMO	AAward	+75K sh	—	—	75,000
2016-10-03	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−3,900 sh	$7.00	−$27.3K	156,715
2016-10-03	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−100 sh	$7.01	−$701	156,615
2016-07-20	CBIOCRESCENT BIOPHARMA, INC.S Sale	SVP Clinical Development, CMO	SSale	−2,000 sh	$8.00	−$16K	160,615

Recent filings

Accepted (ET)
Apr 24
Thackray Helen M.0001127602-25-011136
SEC(opens sec.gov)
Dec 234
Thackray Helen M.0001127602-24-029969
SEC(opens sec.gov)
Dec 174
Thackray Helen M.0001127602-24-029566
SEC(opens sec.gov)
May 154
Thackray Helen M.0001127602-24-015371
SEC(opens sec.gov)
Apr 24
Thackray Helen M.0001127602-24-011832
SEC(opens sec.gov)
Feb 124
Thackray Helen M.0001104659-24-014717
SEC(opens sec.gov)
Jan 34
Thackray Helen M.0001415889-24-000372
SEC(opens sec.gov)
Dec 204
Thackray Helen M.0001127602-23-030189
SEC(opens sec.gov)
Dec 184
Thackray Helen M.0001127602-23-029839
SEC(opens sec.gov)
Oct 24
Thackray Helen M.0001415889-23-013759
SEC(opens sec.gov)
Jul 54
Thackray Helen M.0001415889-23-010819
SEC(opens sec.gov)

Companies

Address

C/O GLYCOMIMETICS, INC. 401 PROFESSIONAL DRIVE, SUITE 250

GAITHERSBURG, MD, 20879